Sai Life Sciences IPO is a book built issue of Rs 3,042.62 crores. The issue is a combination of fresh issue of 1.73 crore shares aggregating to Rs 950.00 crores and offer for sale of 3.81 crore shares aggregating to Rs 2,092.62 crores.
Sai Life Sciences IPO opens for subscription on December 11, 2024 and closes on December 13, 2024. The allotment for the Sai Life Sciences IPO is expected to be finalized on Monday, December 16, 2024. Sai Life Sciences IPO will list on BSE, NSE with tentative listing date fixed as Wednesday, December 18, 2024.
Sai Life Sciences IPO price band is set at ₹522 to ₹549 per share. The minimum lot size for an application is 27 Shares. The minimum amount of investment required by retail investors is ₹14,823. The minimum lot size investment for sNII is 14 lots (378 shares), amounting to ₹207,522, and for bNII, it is 68 lots (1,836 shares), amounting to ₹1,007,964.
Kotak Mahindra Capital Company Limited, Jefferies India Private Limited, Morgan Stanley India Company Pvt Ltd and Iifl Securities Ltd are the book running lead managers of the Sai Life Sciences IPO, while Kfin Technologies Limited is the registrar for the issue.
Refer to Sai Life Sciences IPO RHP for detailed information.
Sai Life Sciences IPO Details
| IPO Date | December 11, 2024 to December 13, 2024 |
| Listing Date | [.] |
| Face Value | ₹1 per share |
| Price Band | ₹522 to ₹549 per share |
| Lot Size | 27 Shares |
| Total Issue Size | 55,421,123 shares (aggregating up to ₹3,042.62 Cr) |
| Fresh Issue | 17,304,189 shares (aggregating up to ₹950.00 Cr) |
| Offer for Sale | 38,116,934 shares of ₹1 (aggregating up to ₹2,092.62 Cr) |
| Issue Type | Book Built Issue IPO |
| Listing At | BSE, NSE |
| Share holding pre issue | 190,685,340 |
| Share holding post issue | 207,989,529 |
Sai Life Sciences IPO Reservation
| Investor Category | Shares Offered |
|---|---|
| QIB Shares Offered | Not more than 50% of the Net Issue |
| Retail Shares Offered | Not less than 35% of the Net Issue |
| NII (HNI) Shares Offered | Not less than 15% of the Net Issue |
Sai Life Sciences IPO Timeline (Tentative Schedule)
Sai Life Sciences IPO opens on December 11, 2024, and closes on December 13, 2024.
| IPO Open Date | Wednesday, December 11, 2024 |
| IPO Close Date | Friday, December 13, 2024 |
| Basis of Allotment | Monday, December 16, 2024 |
| Initiation of Refunds | Tuesday, December 17, 2024 |
| Credit of Shares to Demat | Tuesday, December 17, 2024 |
| Listing Date | Wednesday, December 18, 2024 |
| Cut-off time for UPI mandate confirmation | 5 PM on December 13, 2024 |
Sai Life Sciences IPO Lot Size
Investors can bid for a minimum of 27 shares and in multiples thereof. The below table depicts the minimum and maximum investment by retail investors and HNI in terms of shares and amount.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 27 | ₹14,823 |
| Retail (Max) | 13 | 351 | ₹192,699 |
| S-HNI (Min) | 14 | 378 | ₹207,522 |
| S-HNI (Max) | 67 | 1,809 | ₹993,141 |
| B-HNI (Min) | 68 | 1,836 | ₹1,007,964 |
| Lot Size Calculator | |||
Sai Life Sciences IPO Promoter Holding
The promoters of the company are Kanumuri Ranga Raju, Krishnam Raju Kanumuri, Kanumuri Mytrey, Sai Quest Syn Private Limited, Sunflower Partners, Lily Partners, Marigold Partners and Tulip Partners.
| Share Holding Pre Issue | 40.48% |
| Share Holding Post Issue |
About Sai Life Sciences Limited
Incorporated in January 1999, Sai Life Sciences Limited researches, develops, and manufactures small-molecule new chemical entities. The company offers tailor-made services to biotech firms and global pharma companies.
In the Financial Year 2024 and for the month ending September 30, 2024, the company provided services to over 280 innovator pharmaceutical companies, including more than 230 in that month alone. Among these clients, the company worked with 18 of the top 25 pharmaceutical companies based on their revenue in the calendar year 2023.The services were offered across countries such as the US, the UK, Europe, and Japan.
The company’s business development team consists of 16 experienced and qualified professionals, with six located in the US, nine in the UK and Europe, and one in Japan.
The company has the following service offerings.
- Capabilities in chemistry, manufacturing, and control(“CMC”)/contract development and manufacturing organisations (“CDMO”).
- CRO services include integrated discovery (“Discovery”) capabilities across biology, chemistry, drug metabolism and pharmacokinetics
As of September 30, 2024, the company had 2,353 scientific staff, with the majority of the scientific team holding advanced degrees, including 302 Ph. D.s and 1,475 master’s degrees.
As of September 30, 2024, the company had 3135 employees with capabilities across the CRDMO value chain.
Competitive Strength:
- As an integrated CRDMO, the company provide a complete platform for discovery, development, and manufacturing.
- CRO services include integrated discovery capabilities across biology, chemistry, and drug metabolism and pharmacokinetics.
- CDMO platform with a diverse mix of commercial and under-development molecules
Company Financials
Sai Life Sciences Limited Financial Information (Restated Consolidated)
Sai Life Sciences Limited’s revenue increased by 20% and profit after tax (PAT) rose by 729% between the financial year ending with March 31, 2024 and March 31, 2023.
Key Performance Indicator
The market capitalization of Sai Life Sciences IPO is Rs 11418.63 Cr.
KPI as of March 31, 2024.
| KPI | Values |
|---|---|
| ROE | 11.79% |
| ROCE | 15.96% |
| RoNW | 8.13% |
| P/BV | 10.18 |
| PAT Margin (%) | 5.65 |
Check Sai Life Sciences IPO Peer Comparison here.
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (Rs) | 4.34 | 2.69 |
| P/E (x) | 126.42 | 203.82 |
Note:
- The Pre IPO EPS is calculated based on Pre issue shareholding as on date of RHP and the latest FY earnings as of March 31, 2024 that is available in RHP.
- The Post Issue EPS is calculated based on the Post issue shareholding and annualized FY earnings of September 30, 2024 that is available in RHP.
Objects of the Issue (Sai Life Sciences IPO Objectives)
The company propose to utilise the Net Proceeds towards funding the following objects:
- Repayment/prepayment in full or part, of all or certain outstanding borrowings availed by the Company and
- General corporate purposes
Sai Life Sciences IPO Review (May apply)
[Dilip Davda] The company is innovation focused CRDMO, NCE, CRO, and CMC entity, and a global player for healthcare related products development serving over 25 world’s leading pharma companies. It marked steady growth in its top lines, but the sudden boost in bottom lines for FY24 raises eyebrows. Based on FY25 annualized earnings, the issue appears aggressively priced. Well-informed/cash surplus/risk seekers may park moderate funds for long term. Read detail review…
Sai Life Sciences IPO Prospectus
Sai Life Sciences Limited Contact Details
Sai Life Sciences Limited
Plot No. DS-7, IKP Knowledge Park
Turkapally Village, Shameerpet Mandal,
Malkajgiri District, Hyderabad-500078
Phone: +9140 6815 6000
Email: investors@sailife.com
Website: https://www.sailife.com/
Sai Life Sciences IPO Registrar
Kfin Technologies Limited
Phone: 04067162222, 04079611000
Email: sailifesciences.ipo@kfintech.com
Website: https://kosmic.kfintech.com/ipostatus/